BridgeMD
New treatment option for Peri-implantitis
Official title Peri-implantitis Management: Surgical and Maintenance Outcomes
ClinicalTrials.gov ID: NCT07550127
What this study is testing
- What it's testing
- The goal of this clinical trial is to learn how two standard surgical treatments for peri-implantitis affect inflammation around dental implants. Participants will be randomly assigned to receive resective surgery with implantoplasty or resective surgery with mechanical debridement only.
- Time commitment: about 5 years
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- To be enrolled the participant must met the following
- Aged 18 or older.
- In good general health, classified as ASA Physical Status I or II.
- Diagnosed with peri-implantitis requiring resective surgical treatment, characterized by: Bleeding on probing (BOP) around dental implants. Probing...
- Probing depth (PD) ≤ 5 mm
You likely can't join if
- Patients with autoimmune or systemic inflammatory diseases (e.g., lupus, rheumatoid arthritis) that could alter immune cell profiles independent of...
- Chronic use of systemic corticosteroids or immunosuppressants within the past 3 months.
- Uncontrolled diabetes (HbA1c \> 7.5%) due to its potential impact on healing and immune response.
- Active infection or antibiotic use in the 30 days prior to baseline sampling.
- Pregnancy or breastfeeding.
- Inability to undergo venipuncture or tolerate soft tissue biopsy.
See the full eligibility criteria
- To be enrolled the participant must met the following
- Aged 18 or older.
- In good general health, classified as ASA Physical Status I or II.
- Diagnosed with peri-implantitis requiring resective surgical treatment, characterized by: Bleeding on probing (BOP) around dental implants. Probing pocket depths (PPD) greater than 6 mm. Implants in function for over 1...
- Probing depth (PD) ≤ 5 mm
- Bleeding on probing (BOP) ≤ 1 point
- Absence of suppuration (SOP)
- Absence of progressive bone loss compared to pre-treatment bone levels
- Patients with autoimmune or systemic inflammatory diseases (e.g., lupus, rheumatoid arthritis) that could alter immune cell profiles independent of local peri-implant inflammation.
- Chronic use of systemic corticosteroids or immunosuppressants within the past 3 months.
- Uncontrolled diabetes (HbA1c \> 7.5%) due to its potential impact on healing and immune response.
- Active infection or antibiotic use in the 30 days prior to baseline sampling.
- Pregnancy or breastfeeding.
- Inability to undergo venipuncture or tolerate soft tissue biopsy.
- Inability to attend the 3-month follow-up visit or comply with study protocol.
- History of malignancy requiring systemic therapy within the past 5 years.
The study team makes the final eligibility decision.
Where it's taking place
- Pittsburgh, Pennsylvania, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 5 years per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Pittsburgh, Pennsylvania, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.